These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8102512)

  • 1. Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients.
    Licinio J; Seibyl JP; Altemus M; Charney DS; Krystal JH
    Am J Psychiatry; 1993 Sep; 150(9):1408-10. PubMed ID: 8102512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects.
    el-Mallakh RS; Suddath RL; Wyatt RJ
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 May; 17(3):383-91. PubMed ID: 8475320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status.
    McAllister CG; van Kammen DP; Rehn TJ; Miller AL; Gurklis J; Kelley ME; Yao J; Peters JL
    Am J Psychiatry; 1995 Sep; 152(9):1291-7. PubMed ID: 7653683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in interleukin-1 beta and soluble interleukin-2 receptor levels in CSF and serum of schizophrenic patients.
    Barak V; Barak Y; Levine J; Nisman B; Roisman I
    J Basic Clin Physiol Pharmacol; 1995; 6(1):61-9. PubMed ID: 8562579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients.
    Katila H; Hurme M; Wahlbeck K; Appelberg B; Rimón R
    Neuropsychobiology; 1994; 30(1):20-3. PubMed ID: 7969854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.
    Rapaport MH; McAllister CG; Pickar D; Tamarkin L; Kirch DG; Paul SM
    Schizophr Res; 1997 May; 25(2):123-9. PubMed ID: 9187011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased serum levels of interleukin-2 and interleukin-6 in Indian Bengalee schizophrenic patients.
    Singh B; Bera NK; Nayak CR; Chaudhuri TK
    Cytokine; 2009 Jul; 47(1):1-5. PubMed ID: 19502081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.
    Chouinard G; Jones BD
    Am J Psychiatry; 1980 Jan; 137(1):16-21. PubMed ID: 6101522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia.
    Wahlbeck K; Ahokas A; Miettinen K; Nikkilä H; Rimón R
    Schizophr Bull; 1998; 24(3):391-7. PubMed ID: 9718631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment.
    Ebstein RP; Biederman J; Rimon R; Zohar J; Belmaker RH
    Psychopharmacology (Berl); 1976 Dec; 51(1):71-4. PubMed ID: 13448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abnormal neuroleptic/dopamine receptors in schizophrenia.
    Lee T; Seeman P
    Adv Biochem Psychopharmacol; 1980; 21():435-42. PubMed ID: 6103653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine production in drug-free and neuroleptic-treated schizophrenic patients.
    Bessler H; Levental Z; Karp L; Modai I; Djaldetti M; Weizman A
    Biol Psychiatry; 1995 Sep; 38(5):297-302. PubMed ID: 7495923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
    Moxon KA; Gerhardt GA; Adler LE
    Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Psychopharmacologic approaches to schizophrenic psychoses].
    Giacardy-Paty M; Soubrouillard C; Blin O
    Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated interleukin-6 in the cerebrospinal fluid of a previously delineated schizophrenia subtype.
    Garver DL; Tamas RL; Holcomb JA
    Neuropsychopharmacology; 2003 Aug; 28(8):1515-20. PubMed ID: 12799618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dopamine systems in the brain, functional classification of different dopamine receptors.
    Ljungberg T
    Acta Psychiatr Belg; 1987; 87(5):523-34. PubMed ID: 2897758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smooth pursuit eye movements in schizophrenia: effects of neuroleptic treatment and caffeine.
    Litman RE; Hommer DW; Clem T; Rapaport MH; Pato CN; Pickar D
    Psychopharmacol Bull; 1989; 25(3):473-8. PubMed ID: 2576322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights into the biology of schizophrenia through the mechanism of action of clozapine.
    Brunello N; Masotto C; Steardo L; Markstein R; Racagni G
    Neuropsychopharmacology; 1995 Nov; 13(3):177-213. PubMed ID: 8602893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.